Device Trial Radar · NCT04248868
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Last checked: Nov 20, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Jun 23, 2020
Primary completion
Jun 22, 2022
Study completion Jun 23, 2022
Sponsor
- Lead sponsor
- Thrombolex, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Jan 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.
Conditions
- Pulmonary Embolism
Interventions
The Bashir™ Endovascular CatheterDevice
The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
r-tPADrug
Pulse spray and infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: RV/LV Ratio DifferenceTime frame: 48 hours after the completion of r-tPA treatment
- Safety: Major BleedingTime frame: Within 72 hours of initiation of r-tPA administration
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
UCLA
Los Angeles, California
Miami Cardiac & Vascular Institute
Miami, Florida
Advent Health Orlando
Orlando, Florida
16 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.